lifestyle.marketresearchjournals.com

Author: Pentixapharm Holding AG

Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program

February 25, 2026
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

February 11, 2026
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension

January 7, 2026